Hillegass, William B.; Newman, Anne R.; Raco, Dominic L. - In: PharmacoEconomics 19 (2001) 1, pp. 41-55
In addition to efficacy and safety, cost is an important determinant of the use of glycoprotein IIb/IIIa (GPIIb/IIIa) therapy in patients with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI). In PCI, the average procurement cost of GPIIb/IIIa therapy ranges...